Cangrelor Better than Plavix, Study
In a new study released this Sunday, cangrelor has proved better as anti-clotting drug than the most commonly used drug for the purpose, plavix.
Cangrelor is in experimental phase and is checked for its efficacy in dealing with blood clotting. Plavix has been used as a standard drug presently but researchers say cangrelor can prove a successful alternative to the same.
Plavix works by preventing platelets from sticking together and creating clot that blocks blood vessels. The study, conducted on some 11,145 patients, revealed that cangrelor is bit ahead of plavix in preventing the clot formation.
The study was presented on at an American College of Cardiology meeting in San Francisco. Findings show that cangrelor was a better drug in comparison to plavix and was more successful in preventing deaths, heart attacks and re-clogging of blood vessels.
However, according to a study led by Deepak Bhatt, the Chief of Cardiology at VA Boston Healthcare System, both the drugs are equally risky in causing bleeding problems.
"The advantage of this drug is that it's ultra short-acting. You can dial on and dial off", said Steven Nissen, the Chairman of cardiology at the Cleveland Clinic. The study was funded by the Medicines Company which manufactures cangrelor.